23092015 PR ladenburg conf_EN
Category: Press release
Transgene Reports Financial Results for First Six Months of 2015 (interim report)
20150910 – PR 2015 H1 results final
Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
20150908 PR TG4010 IASLC revised – BIS
Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer
19 August 2015_PR_IASLC curtain raiser_ENG
Transgene plans restructuring to focus on research and development
20150629 PR 29 juin fin
Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)
20150601 PR TG4010 TIME results_ASCO 2015_FINAL
Transgene Announces Participation at Upcoming Investor Events
20150518 May thru July 2015 IR events_ver 1 ENG
Transgene Presents New Data with TG1050, an Immunotherapy being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015
20150423 – US – EASL2015 TG1050
Transgene Reports First Quarter 2015 Financial Results
20150422 PR US Q1 2015
Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody
20150421 AACR 2015_English
